These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 19395467

  • 1. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
    Yamamoto N, Sekine I, Nakagawa K, Takada M, Fukuoka M, Tanigawara Y, Saijo N.
    Jpn J Clin Oncol; 2009 Jul; 39(7):425-30. PubMed ID: 19395467
    [Abstract] [Full Text] [Related]

  • 2. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S, Shi YK, Liu P, Han XH, He XH, Cai YM, Chen ZM.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
    [Abstract] [Full Text] [Related]

  • 3. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
    Naoki K, Kunikane H, Fujii T, Tsujimura S, Hida N, Okamoto H, Watanabe K.
    Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
    [Abstract] [Full Text] [Related]

  • 4. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
    Heigener DF, Manegold C, Jäger E, Saal JG, Zuna I, Gatzemeier U.
    Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
    [Abstract] [Full Text] [Related]

  • 5. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
    Tan Sean P, Chouaid C, Hettler D, Baud M, Hejblum G, Tilleul P.
    Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340
    [Abstract] [Full Text] [Related]

  • 6. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
    Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F, Ruf L, Haas R, Kobbe G.
    Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322
    [Abstract] [Full Text] [Related]

  • 7. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Blayney DW, McGuire BW, Cruickshank SE, Johnson DH.
    Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
    [Abstract] [Full Text] [Related]

  • 8. A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer.
    Kaira K, Sunaga N, Yanagitani N, Imai H, Utsugi M, Shimizu Y, Iijima H, Tomizawa Y, Hisada T, Ishizuka T, Saito R, Mori M.
    Anticancer Drugs; 2007 Apr; 18(4):471-6. PubMed ID: 17351400
    [Abstract] [Full Text] [Related]

  • 9. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E, Aravantinos G, Xanthakis I, Pentheroudakis G, Pectasides D, Fountzilas G.
    Oncology; 2009 Apr; 77(2):107-12. PubMed ID: 19622901
    [Abstract] [Full Text] [Related]

  • 10. Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer.
    Daga H, Isobe T, Miyazaki M, Fujitaka K, Kondo K, Kohno N.
    Oncol Rep; 2004 Jun; 11(6):1225-31. PubMed ID: 15138560
    [Abstract] [Full Text] [Related]

  • 11. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
    Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G.
    Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
    André N, Kababri ME, Bertrand P, Rome A, Coze C, Gentet JC, Bernard JL.
    Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
    [Abstract] [Full Text] [Related]

  • 13. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer.
    Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ.
    Oncol Rep; 2003 Mar; 10(3):715-24. PubMed ID: 12684649
    [Abstract] [Full Text] [Related]

  • 14. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
    Heaney ML, Toy EL, Vekeman F, Laliberté F, Dority BL, Perlman D, Barghout V, Duh MS.
    Cancer; 2009 Oct 15; 115(20):4839-48. PubMed ID: 19637341
    [Abstract] [Full Text] [Related]

  • 15. Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer.
    Schuman SI, Lambrou N, Robson K, Glück S, Myriounis N, Pearson JM, Lucci JA.
    J Support Oncol; 2009 Oct 15; 7(6):225-8. PubMed ID: 20380330
    [Abstract] [Full Text] [Related]

  • 16. Pegfilgrastim for chemotherapy-induced neutropenia.
    Bedell C.
    Clin J Oncol Nurs; 2003 Oct 15; 7(1):55-6, 63-4. PubMed ID: 12629935
    [Abstract] [Full Text] [Related]

  • 17. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.
    Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL, Chen H, Schuening FG.
    Bone Marrow Transplant; 2005 Jun 15; 35(12):1165-9. PubMed ID: 15880129
    [Abstract] [Full Text] [Related]

  • 18. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
    Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, Dreiling L.
    Oncologist; 2007 Apr 15; 12(4):484-94. PubMed ID: 17470691
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
    Yanagitani N, Tsuchiya S, Kaira K, Sunaga N, Tsuchiya Y, Sato K, Watanabe S, Nomura S, Sakai S, Saito R, Mori M.
    Am J Clin Oncol; 2007 Oct 15; 30(5):487-91. PubMed ID: 17921708
    [Abstract] [Full Text] [Related]

  • 20. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
    Whitworth JM, Matthews KS, Shipman KA, Numnum TM, Kendrick JE, Kilgore LC, Straughn JM.
    Gynecol Oncol; 2009 Mar 15; 112(3):601-4. PubMed ID: 19110303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.